Fernández Alonso Ana Maria, Varikasuvu Seshadri Reddy, Pérez-López Faustino R
Department of Obstetrics and Gynecology, Torrecárdenas University Hospital, Almería, Paraje Torrecárdenas s/n 04009 Spain.
Department of Biochemistry, All India Institute of Medical Sciences, Deoghar, Jharkhand India.
J Diabetes Metab Disord. 2024 Dec 27;24(1):24. doi: 10.1007/s40200-024-01513-4. eCollection 2025 Jun.
We performed a systematic review and meta-analysis to examine the associations between telomere length and telomerase activity in subjects with and without metabolic syndrome (MetS).
The meta-analysis protocol was registered in the PROSPERO database. The PubMed, Embase, Cochrane Library, and LILACS databases were searched for studies reporting telomere length or telomerase activity in adult men and non-pregnant women with and without MetS. The risk of bias was assessed with the Newcastle-Ottawa Scale. Random effects and inverse variance methods were used to meta-analyze associations. We conducted a bootstrapped analysis to test the accuracy of clinical results.
Five studies reported telomere length and two studies telomerase activity. There was no significant difference in telomere length (standardized mean difference [SMD]: 0.10, 95% confidence interval [CI]: -0.07, 0.28, : 54%), between subjects of similar age (mean difference: 2.68, 95%CI: -0.04, 5.40 years) with and without the MetS. Subjects with MetS displayed significantly higher body mass index, triglycerides, and blood pressure, and lower HDL-cholesterol values than subjects without the syndrome. A bootstrapping mediation analysis of telomere length confirmed the clinical results. There was no significant difference in telomerase activity (SMD: 1.19, 95% CI -0.17, 2.55, : 93%) between subjects with and without the MetS.
There were no significant differences of telomere length and telomerase activity in patients with MetS and subjects of similar age without the syndrome.
The online version contains supplementary material available at 10.1007/s40200-024-01513-4.
我们进行了一项系统综述和荟萃分析，以研究代谢综合征（MetS）患者与非患者的端粒长度和端粒酶活性之间的关联。
荟萃分析方案已在PROSPERO数据库中注册。检索了PubMed、Embase、Cochrane图书馆和LILACS数据库，以查找报告有或无MetS的成年男性和非妊娠女性的端粒长度或端粒酶活性的研究。使用纽卡斯尔-渥太华量表评估偏倚风险。采用随机效应和逆方差方法对关联进行荟萃分析。我们进行了自抽样分析以检验临床结果的准确性。
五项研究报告了端粒长度，两项研究报告了端粒酶活性。在年龄相似（平均差异：2.68，95%置信区间：-0.04，5.40岁）的有和无MetS的受试者之间，端粒长度没有显著差异（标准化平均差异[SMD]：0.10，95%置信区间：-0.07，0.28，I²：54%）。与无该综合征的受试者相比，患有MetS的受试者的体重指数、甘油三酯和血压显著更高，高密度脂蛋白胆固醇值更低。对端粒长度的自抽样中介分析证实了临床结果。有和无MetS的受试者之间端粒酶活性没有显著差异（SMD：1.19，95%置信区间-0.17，2.55，I²：93%）。
患有MetS的患者与年龄相似的无该综合征的受试者在端粒长度和端粒酶活性方面没有显著差异。
在线版本包含可在10.1007/s40200-024-01513-4获取的补充材料。
